The effects of conjugated equine estrogens plus cyclical dydrogesterone on serum lipoproteins and apoproteins in postmenopausal women.
Serum lipoprotein and apoprotein concentrations were monitored for 24 weeks in 26 postmenopausal women treated with conjugated equine estrogens (0.625 mg/day) with the addition of dydrogesterone (10 mg/day) for the last 12 days of each 28 day cycle. The women had had no previous hormone replacement therapy. The estrogen plus dydrogesterone regimen caused significant (P less than 0.05) increases in triacylglycerol and HDL cholesterol concentrations. Both HDL2 and HDL3 cholesterol were increased. There were no other significant changes in lipoprotein concentrations. Both apoprotein AI and apoprotein AII concentrations increased significantly (P less than 0.05) over the study period. The ratios of apoprotein AI to apoprotein AII, apoprotein AI to HDL cholesterol and apoprotein AII to HDL cholesterol did not change. At the doses employed in this study, the use of dydrogesterone as a progestogen alters the effects of conjugated equine estrogens on lipoproteins and reinforces the view that the effects of a combined HRT regimen cannot be predicted from a consideration of the effects of the individual components.
Fletcher
C D
CD
Department of Biochemistry, Stobhill General Hospital, Glasgow, Scotland.
Farish
E
E
Dagen
M M
MM
Alazzawi
F
F
McQueen
D
D
Hart
D M
DM
D001059:Apoproteins / Q000097:blood*; D004359:Drug Therapy, Combination; D004394:Dydrogesterone / Q000008:administration & dosage*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008593:Menopause / Q000097:blood*; D008875:Middle Aged
D001059:Apoproteins; D004966:Estrogens, Conjugated (USP); D008074:Lipoproteins; D004394:Dydrogesterone